Associations - BCR-ABL1 mutation

BIOMARKER:

BCR-ABL1 mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + nilotinib Sensitive: C3 – Early Trials venetoclax + nilotinib Sensitive : C3
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + bosutinib Sensitive: C3 – Early Trials venetoclax + bosutinib Sensitive : C3
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + ponatinib Sensitive: C3 – Early Trials venetoclax + ponatinib Sensitive : C3
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + dasatinib Sensitive: C3 – Early Trials venetoclax + dasatinib Sensitive : C3
BCR-ABL1 mutation BCR-ABL1 mutation	Acute Myelogenous Leukemia AML	venetoclax + dasatinib Sensitive: C3 – Early Trials venetoclax + dasatinib Sensitive : C3
BCR-ABL1 mutation BCR-ABL1 mutation	Acute Myelogenous Leukemia AML	venetoclax + ponatinib Sensitive: C3 – Early Trials venetoclax + ponatinib Sensitive : C3